Stay updated on Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.

Latest updates to the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
- Check40 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check54 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check61 days agoChange DetectedThe latest update includes a revision of the study protocol, specifically noting that the Data Monitoring Committee is no longer applicable, and changes to participant assessments, including the discontinuation of electronic patient-reported outcome assessments and biomarker sample collections.SummaryDifference1%
- Check90 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.